Mintz Represents Intarcia Therapeutics, Inc. in Landmark $200 Million Private Financing
Attorneys in the Corporate & Securities and Life Sciences Practices of Mintz, Cohn, Ferris, Glovsky and Popeo, P.C. represented Intarcia Therapeutics, Inc. in the completion of a private round of equity financing for $200 million. With this financing, Intarcia Therapeutics, Inc. became the highest-valued privately held biotech in the history of the industry.
Intarcia is a rapidly emerging biotech company committed to developing and commercializing innovative therapies that merge medicine with technology and have the potential to transform therapeutic outcomes in chronic serious diseases.
The Mintz team was led by Jonathan L. Kravetz, Chair of the firm’s Securities Practice Group and one of the core members of the Life Sciences Practice Group, Scott A. Samuels, a Member of the Corporate & Securities Practice and Life Sciences Practice, and Kristin A. Gerber and J.R. Urbon, associates in the Corporate & Securities Practice.
Mintz has served as one of the leading law firms to the life sciences industry since the industry’s birth in the 1970s. Today, we advise hundreds of businesses and other organizations in all sectors of the industry’s ecosystem -- from start-ups looking for their first funding to public companies with products on the market, as well as venture capital firms, investment banks, and research and academic institutions. Our attorneys provide experienced counsel to clients globally in a broad range of matters, including corporate finance and securities, mergers and acquisitions, licensing and collaborations, intellectual property, litigation, regulatory, antitrust, employment and benefits, bankruptcy and commercial lending, immigration, and real estate. Mintz is a full-service law firm comprised of 470 attorneys with eight offices (Boston, New York, San Diego, San Francisco, Washington, Stamford, Los Angeles, and London) and an affiliate relationship in Israel.